This observational study evaluated the clinical and angiographic outcomes of patients with aorto-ostial coronary artery disease treated with sirolimus-eluting stents (SESs) or with bare metal stents (BMSs). BACKGROUND The safety and effectiveness of SESs for the treatment of aorto-ostial lesions have not been demonstrated.
Previous studies with bare metal stents (BMSs) showed that aorto-ostial lesions have higher restenosis rates than nonaorto-ostial lesions (1) (2) (3) (4) . Traditionally, the presence of an aorto-ostial stenosis poses a special management problem for the interventionalist in that ostial lesions are the most likely to be associated with suboptimal angiographic results due to lesion rigidity and recoil (1, 2, 4, 5) . Although stents provide adequate scaffolding to prevent recoil, in-stent restenosis is mainly due to neointimal hyperplasia. Sirolimus-eluting stents (SESs) (Cypher, Cordis/Johnson & Johnson, Warren, New Jersey) have been shown to reduce neointimal hyperplasia and risk of restenosis (6, 7) . However, the issue of SES implantation in aorto-ostial lesions has not been adequately evaluated, because these patients were excluded or minimally represented in the multicenter randomized trials versus patients treated with BMSs. The purpose of this study was to evaluate the safety and effectiveness of the SES implantation in aorto-ostial lesions.
METHODS
We evaluated retrospectively 32 consecutive patients who underwent percutaneous coronary interventions in 32 aortoostial lesions using the SES between April 2002 and March 2003. A control group for comparison was composed of 50 consecutive patients who underwent treatment of aortoostial lesions (50 lesions) with the BMS during the period immediately before the introduction of the SES. The following BMSs were used: BX Sonic or BX Velocity (Cordis/Johnson & Johnson) in 28%; JoMed polytetrafluoroethylene (PTFE)-covered stent (JoMed, Rangendingen, Germany) in 14%; Multi-Link Penta (Guidant Corp., Santa Clara, California) in 10%; Diamond-Flex (Phytis, Dreieich, Germany) in 10%; Multi-Link Tetra (Guidant Corp.) in 5%; Sorin Carbon (Sorin Biomedica, Saluggia, Italy) in 8%; and other stents in 27%.
All patients were pre-treated with ticlopidine or clopidogrel and aspirin at least three days before the procedure; a loading dose of 300 mg clopidogrel was administered to those who were not pre-treated. Aspirin was continued indefinitely and clopidogrel or ticlopidine for at least three months after SES and for one month following BMS implantation. Stent implantation methods have been described previously (8) . All stents were implanted with high-pressure (Ͼ12 atm) final balloon dilatation with an attempt to fully cover the angiographic lesion and to ensure complete stent apposition.
Glycoprotein IIb/IIIa inhibitors were administered at the operator's discretion. Angiographic analysis. Cineangiograms were analyzed using a validated edge detection system (Version 5.2, CMS, MEDIS, The Netherlands). Standard qualitative and quantitative definitions and measurements were used. Using the contrast-filled catheter as the calibration standard, minimal lumen diameter (MLD), reference diameter, and percent diameter stenosis (DS) before and after coronary intervention were obtained from the single "worst" and least foreshortened view. Aorto-ostial lesions were defined as lesions involving the junction between the aorta and the orifice of the right coronary artery, left main, or a saphenous vein graft within 3 mm of the vessel ostia.
Angiographic success was defined as a final residual stenosis less than 30%. Angiographic restenosis was defined as Ͼ50% DS by quantitative coronary angiography within a previously stented vessel segment. Late lumen loss was defined as the difference between the MLD at the completion of the stenting procedure and that measured at followup. These are standard qualitative and quantitative analyses and definitions, and they have been published previously (9) . Clinical definitions and follow-up. Pre-specified clinical and laboratory demographic information was obtained from hospital charts that were reviewed by independent research personnel; data were entered prospectively into a dedicated database. Standard definitions included: 1) Q-wave myocardial infarction (MI): the presence of new pathological Q waves in the electrocardiogram associated with an elevation of cardiac enzyme Ն2 times the upper normal value, and 2) non-Q-wave MI: creatine kinase-MB enzyme elevation Ն3 times the upper normal value without new Q waves.
Clinical follow-up was performed by either telephone contact or office visit. Major adverse cardiac events (MACE) were recorded, including death (all-cause), Q-wave MI, and target lesion revascularization (TLR) and 
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target vessel revascularization (TVR) (whether percutaneous or surgical). Statistical analysis. Statistical analysis was performed using SPSS, version 11 (SPSS Inc., Chicago, Illinois). Continuous variables are expressed as mean Ϯ1 SD and categorical variables as frequency (%). Continuous variables were compared using independent samples t test. Categorical variables were compared with chi-square statistics.
RESULTS
Baseline patient and lesion characteristics. The baseline clinical and lesion characteristics of the patient population were similar between the two groups, except for a higher incidence of hypertension and hypercholesterolemia and a lower mean ejection fraction in the SES group (Table 1) . Patients with the BMS had a trend toward higher incidence of unstable angina. Out of the 20 left main coronary artery lesions, 9 (45%) were unprotected; 5 in the SES and 4 in the BMS group. Procedural data and in-hospital outcome. The procedural data and in-hospital outcome are shown in Table 2 . All stents were deployed successfully. The SES group, compared to the BMS, had a smaller mean maximum balloon diameter (3.50 vs. 3.82 mm, p ϭ 0.003) and a longer mean stent length per lesion (24.81 vs. 13.71 mm, p Ͻ 0.0001). There were no statistically significant differences regarding procedural and major in-hospital complications. All procedures except one (2%) of the BMS group resulted in Thrombolysis In Myocardial Infarction (TIMI) flow grade 3. There were no cases of acute stent thrombosis, perforations, or residual dissections. One (3.1%) patient in the SES group suffered a nonfatal, in-hospital Q-wave MI. Non-Qwave MI occurred in three (9.3%) SES patients compared to seven (14%) of the BMS group (p ϭ 0.7). Clinical outcome. One-month follow-up was available in all patients, and no additional events (including subacute thrombosis) were recorded (data not shown). Ten-month cumulative clinical follow-up was available in all patients and is shown in Figure 1 . Patients with the SES had lower TLR compared to patients with the BMS (6.3% vs. 28%, p ϭ 0.03). One patient of the SES group suffered late-stent thrombosis presented as an acute MI and died four months post-procedure after discontinuation of antiplatelet therapy. There was a trend toward less frequent TVR in the SES group (16% vs. 34%, p ϭ 0.06). In addition, the incidence 
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Sirolimus-Eluting Stents in Aorto-Ostial Lesions of 10-month MACE was significantly lower in the SES compared to the BMS group (19% vs. 44%, p ϭ 0.02). Quantitative coronary angiography. Quantitative coronary angiographic analysis is shown in Table 3 . The mean reference vessel diameter was 3.17 mm for the SES and 3.47 mm for the BMS group (p ϭ 0.1). The SES group had a trend (p ϭ 0.07) toward smaller MLD compared to the BMS group. Post-intervention reference vessel diameter and MLD were significantly larger in the BMS group. Angiographic follow-up was available in 88% of the SES patients versus 70% of the BMS patients (p ϭ 0.1). The mean time to angiographic follow-up did not differ significantly between the two groups (7.4 vs. 6.3 months, p ϭ 0.08). The rate of restenosis for the lesions treated with PTFE stents was 50% (three of six lesions with available angiographic follow-up) and did not differ significantly from the restenosis rate of the other stents of the BMS group (52%, p ϭ 0.7). Binary restenosis occurred less frequently in the SES group (11% vs. 51%, p ϭ 0.001). All three restenotic lesions in the SES group were focal (Յ10 mm in length). Conversely, only 9 (50%) of the 18 restenotic lesions in the BMS group were focal. In addition, late loss was significantly smaller in the SES compared to the BMS group (0.21 Ϯ 0.31 mm vs. 2.06 Ϯ 1.37 mm, p Ͻ 0.0001).
DISCUSSION
The main finding of our study is that, compared to the BMS, implantation of the SES in aorto-ostial lesions appears safe and effective, with no increase in major inhospital complications and a significant improvement in restenosis and late event rates at 10-month follow-up.
The findings of the current study are similar to the results of the major drug-eluting stent randomized trials, which invariably showed dramatic decrease in restenosis rates with the use of the SES (6,7). As expected, late loss in the SES group was significantly smaller compared to the BMS group. However, the mean late loss of 0.21 mm was slightly larger than the respective values of the landmark randomized trials of the SES versus the BMS. More specifically, the mean late loss was Ϫ0.01 mm in the RAVEL (Randomized study with the sirolimus-eluting Bx VELocity balloonexpandable stent) and 0.17 mm in the SIRIUS (A U.S. multicenter, randomized, double-blind study of the SIRolImUS-eluting stent in de novo native coronary lesions) (6, 7) . Lesion rigidity might be a possible explanation for this finding. Histologic data from pathologic series (10) and atherectomy specimens (11) showed that ostial lesions are frequently heavily calcified, fibrotic, and sclerotic. It has also been suggested that there may be more elastic recoil even after stent implantation at ostial sites because of the highly elastic tissue in the adjacent aortic wall (1, 10) . Therefore, stenting at ostial site may respond differently than other segments of the coronary artery. Furthermore, the nonavailability of 3.5-mm SES (seven-cell stent) in our center at the time of patient enrollment for the present study may have resulted in a slight mismatch of the vessel size and the stent diameter and thus to stent overexpansion or less homogeneous drug distribution in the SES group.
In our study, the SES group had significantly smaller post-intervention MLD compared to the BMS group; thus it consisted of lesions more prone to restenosis. Furthermore, 38% of the SES lesions were restenotic compared to 22% of the BMS lesions (p ϭ 0.2). The discrepancy in the SES group between the TLR rate of 6.3% and the TVR rate of 16% is due to treatment of other lesions distal to the stented segments which were not stented at the time of the index procedure. Study limitations. The major limitations of this study are the small sample size, the different percentages of angiographic follow-up in the two groups, and some imbalance in
